Trimetazidine hydrochloride sustained release tablet and preparation method thereof

Abstract

The invention discloses a trimetazidine hydrochloride sustained release tablet and a preparation method thereof, and belongs to the field of western medicine preparation, the sustained-release tablet is prepared from the following components in parts by weight: 10-50 parts of trimetazidine hydrochloride, 100-200 parts of a gel skeleton material, 100-300 parts of filler, 40-80 parts of a glidant and 5-10 parts of a lubricant; the preparation method comprises the following steps: respectively crushing the trimetazidine hydrochloride, the gel skeleton material, the glidant and the filler into powder with the particle size controlled in 20-40 mesh, then mixing evenly, then adding the lubricant powder, mixing evenly to obtain a mixture; putting the mixture into a tabletting machine, tabletting, drying in an oven, and finally packaging. Using hydroxypropyl cellulose as the matrix skeleton material, the drug sustained release effect can be ensured, the preparation method is simple, easy to operate, and suitable for industrial mass production, and the tablet is convenient to carry, and easy for patients to carry and take.

Description

technical field [0001] The invention belongs to the field of western medicine preparation, and in particular relates to a trimetazidine hydrochloride sustained-release tablet and a preparation method thereof. Background technique [0002] Angina pectoris is a relatively common disease in coronary atherosclerotic heart disease (coronary heart disease). imbalance between. Trimetazidine hydrochloride is an anti-anginal cardiovascular drug, which prevents the decline of intracellular ATP levels by protecting the energy metabolism of cells under hypoxic or ischemic conditions, thus ensuring the normal function of ion pumps and transmembrane sodium-potassium flow normal operation and maintain the stability of the intracellular environment. Trimetazidine hydrochloride is clinically used for preventive treatment of angina pectoris attack, auxiliary symptomatic treatment of vertigo and tinnitus, etc. [0003] The main technology of currently commercially available trimetazidine hy...

AI Technical Summary

Problems solved by technology

[0003] At present, the main technology of trimetazidine hydrochloride sustained-release tablets on the market is to use hypromellose as the gel matrix material, which makes the sustained-release stability of the drug poor and the drug effect is not significant enough